MilliporeSigma has signed a license agreement providing Evotec SE access to its foundational CRISPR technology. Evotec, an international biotechnology company headquartered in Hamburg, Germany, will use MilliporeSigma’s CRISPR genome-editing technology to create edited cell lines for Evotec’s commercial and internal research purposes.   “This CRISPR license is the impetus for important drug testing and discovery that promises to accelerate research and lead to the development o...